AZ&Me sees participation increase in 2010
WILMINGTON, Del. — Nearly half a million people participated in AstraZeneca’s prescription savings programs.
The drug maker reported that it provided $947 million in savings last year to the more than 545,000 patients in the United States who participated. Participation in the AZ&Me prescription savings programs has increased steadily over the past three years, up 7% over 2009 and 19% over 2008, AstraZeneca said.
An interactive map of the numbers of patients in AZ&Me programs in each state can be found here.
Mylan looks to market generic Lidoderm
CHADDS FORD, Pa. — Mylan has announced its intention to market a version of a painkiller made by Endo Pharmaceuticals and partner company Teikoku Seiyaku ahead of patent expiration.
Endo said Monday that Teikoku Seiyaku and U.S. subsidiary Teikoku Pharma USA had received a Paragraph IV certification from Mylan stating the latter’s intention to market a generic lidocaine topical patch. The drug is a generic version of Endo’s and Teikoku’s Lidoderm.
Under the Hatch-Waxman Act of 1984, a Paragraph IV certification is an assertion included with a regulatory approval application that the patents covering a drug are invalid, unenforceable or won’t be infringed by a generic version. In this case, the certification refers to patents that expire in March 2014 and October 2015.
Endo said it would “vigorously defend” its intellectual property rights. Under Hatch-Waxman, the drug maker is allowed to sue Mylan for patent infringement, which would put an automatic stay of final Food and Drug Administration approval on Mylan’s generic version that would expire after 30 months or when the companies reach a settlement.
Pfizer: Tender offer for King completed
NEW YORK — Pfizer has completed its tender offer for Bristol, Tenn.-based King Pharmaceuticals, Pfizer said Monday.
Pfizer said 230.7 million shares valued at $14.25 each were tendered, representing about 92.5% of King.
Pfizer made its $3.6 billion offer for King in October 2010. The offer cleared the waiting period mandated by the Hart-Scott-Rodino Antitrust Improvements Act of 1976 on Friday.